Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 11:01 ET | Source: Sobi, Inc.

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions

NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS...
October 06, 2025 11:07 ET | Source: Spherix Global Insights

US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights

EXTON, PA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable...
August 19, 2025 09:28 ET | Source: Trethera Corporation

Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus

$3M NIH grant advances TRE-515, a first-in-class lupus therapy. Funding supports safety, biomarker studies, and paves the way for patient trials.
August 12, 2025 22:30 ET | Source: Custom Market Insights

[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Personalized Medicine Market Size, Trends and Insights By Product...
August 07, 2025 09:34 ET | Source: Spherix Global Insights

Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights

EXTON, PA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies...
July 23, 2025 12:51 ET | Source: Spherix Global Insights

Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports

EXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) -- Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe...
June 17, 2025 15:01 ET | Source: Spherix Global Insights

Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights

EXTON, PA, June 17, 2025 (GLOBE NEWSWIRE) -- According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and...
June 17, 2025 07:32 ET | Source: Research and Markets

Antibody Collaboration and Licensing Agreements Analysis Report 2025 with Directory of Deals - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area

Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering.Antibody Collaboration and Licensing...
June 02, 2025 10:07 ET | Source: Spherix Global Insights

Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights

EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is...
April 30, 2025 13:39 ET | Source: Spherix Global Insights

Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights

EXTON, PA, April 30, 2025 (GLOBE NEWSWIRE) -- The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis (LN) have led specialists to reconsider their...